Please assess the completion status of the following clinical trial:

Trial Title: Effect of the Known Antihypertensive Drug Telmisartan on Red Blood Cells and Circulation in the Smallest Blood Vessels

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men older than 18 years~* Diabetes mellitus type 2 defined according to the criteria of the American Diabetes Association Arterial hypertension defined according to the criteria of the Joint National Committtees (JNC 7)~* Given informed consent~Exclusion Criteria:~* Serve heart failure~* Serve aortic valve stenosis or hypertrophy obstructive cardiomyopathy~* Relevant cardiac arrhythmias~* Acute myocardial infarction within the last 4 weeks~* renal failure~* bilateral renal artery stenosis~* liver diseases~* primary hyperaldosteronism~* orthostatic hypotension (systolic blood pressure \<100mmHg)~* hypokalemia, hyponatremia, hypercalcemia, symptomatic hyperuricemia~* inflammatory disease~* malignant disease~* previous intolerance to AT1 receptor antagonists and/or sulfonamides~* current therapy with insulin sensitizer~* current therapy with digoxin~* known abuse of alcohol or drugs

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): treatment with 80 mg Telmisartan per day for 30 days
- B (Type: ACTIVE_COMPARATOR): treatment with 20mg Telmisartan per day for 30 days

Based on this trial design, predict the completion outcome and termination type (if applicable).